CTV to PTV Margins Based On CBCT Method for Prostate Cancer of Patients Treated With VMAT Technique

Document Type : Original Paper

Authors

1 Laboratory of high energy physics Modelisation Simulation, Faculty of Sciences, University Mohammed V, Rabat, Morocco

2 Hassan First University of Settat, High Institute of Health Sciences, Laboratory of Sciences and Health Technologies, Settat, Morocco

3 Departement of Physics, Laboratory of High Energy Physics, Modelling and Simulation, Faculty of Science, Mohammed V Agdal University, Rabat, Kingdom of Morocco

Abstract

Introduction: Patient repositioning in treatment radiotherapy is one of the main factors that increase error of target irradiation. However additional margin is necessary to consider the uncertainties created along and around X, Y and Z-axis.
Material and Methods: Set-up and random errors were calculated in translational and rotational axis for a sample of 20 prostatic patients; using daily IGRT-CBCT method. The aim of this study was to determine the additional margin that should be added from clinical target volume (CTV) to prevent toxicity and increase the irradiation precision in radiotherapy. The van Hark formula (PTV margin =2.5Σ +0.7σ) was used for all patients to perform PTV margin for prostatic localization.
Results: The research performed for a sample of 20 consecutive patients. With respect to systematic error along the lateral axis, longitudinal and anterior-posterior was 2.32, 2.42 and 3.54 respectively. The Random error was 1.82, 2.19 and 1.76° along lateral axis, longitudinal and anterior-posterior respectively. The rotational systematic error was 1.49, 2.04 and 2.14° around lateral, longitudinal and anterior-posterior axis respectively. The Random error was 1.78, 1.75 and 1.63° around lateral, longitudinal and anterior-posterior axis respectively. The calculated safety margin to cover clinical target volume (CTV) taking the prostate variability into account measured 7.55, 8.08 and 10.79 mm for lateral, longitudinal and anterior posterior respectively and 7mm would be enough in the posterior side. Rotational set-up errors for almost 95% of patients were between -2° and 2°.
Conclusion: The calculated safety margin in all direction was smaller than 1 cm except in anterior side that was 1 cm or more.

Keywords

Main Subjects

References

  1. Wu VW , Law MY, Star-Lack J, Cheung FW, Ling CC. Technologies of image guidance the development of advanced linear accelerator system for radiotherapy. Front Radiat Ther Oncol. 2011; 43:132-64.
  2. Kim J, Meyer JL, Dawson LA. Image guidance and the new practice of radiotherapy: what to know and use from a decade of investigation. Front Radiat Ther Oncol. 2011; 43:196-216.
  3. Verbakel WF, Cuijpers JP, Hoffmans D, Bieker M, Slotman BJ, Senan S. Volumetric intensity-modulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and dosimetric study. Int J Radiat Oncol Biol Phys. 2009;74:252–9
  4. Quan EM, Li X, Li Y, Wang X, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK, Zhang X. A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment. International Journal of Radiation Oncology* Biology* Physics. 2012 Jul 15;83(4):1169-78.
  5. Palma D, Vollans E, James K, Nakano S, Moiseenko V, Shaffer R, et al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. International Journal of Radiation Oncology* Biology* Physics. 2008 Nov 15;72(4):996-1001.
  6. Bedford JL. Treatment planning for volumetric modulated arc therapy.Med Phys. 2009;36:5128e5138.
  7. Wolff D, Stieler F, Welzel G, Lorenz F, Abo-Madyan Y, Mai S, et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiotherapy and oncology. 2009 Nov 1;93(2):226-33.
  8. Palma D, Vollans E, James K, Nakano S, Moiseenko V, Shaffer R, et al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. International Journal of Radiation Oncology* Biology* Physics. 2008 Nov 15;72(4):996-1001.
  9. Youssoufi MA, Bougtib M, Douama S, Erraisse MA, Abboud FZ, Hassouni K, et al. Evaluation of PTV margins in IMRT for head and neck cancer and prostate cancer. Journal of Radiotherapy in Practice. 2021 Mar;20(1):114-9.
  10. Wortel RC, Incrocci L, Pos FJ, Lebesque JV, Witte MG, van der Heide UA, et al. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients. International Journal of Radiation Oncology* Biology* Physics. 2015 Mar 15;91(4):737-44.
  11. Graf R, Wust P, Budach V, Boehmer D. Potentials of on-line repositioning based on implanted fiducial markers and electronic portal imaging in prostate cancer radiotherapy. Radiat Oncol. 2009; 4: 13-21.
  12. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Physics in Medicine & Biology. 2004 Sep 3;49(18):N309.
  13. Rahman WN, Bishara N, Ackerly T, He CF, Jackson P, Wong C, et al. Enhancement of radiation effects by gold nanoparticles for superficial radiation therapy. Nanomedicine: Nanotechnology, Biology and Medicine. 2009 Jun 1;5(2):136-42.
  14. Roa W, Zhang X, Guo L, Shaw A, Hu X, Xiong Y, et al. Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle. Nanotechnology. 2009 Aug 26;20(37):375101.
  15. Chithrani DB, Jelveh S, Jalali F, van Prooijen M, Allen C, Bristow RG, et al. Gold nanoparticles as radiation sensitizers in cancer therapy.  Radiat Res 2010;173(6):719-28.
  16. Hainfeld JF, Dilmanian FA, Zhong Z, Slatkin DN, Kalef-Ezra JA, Smilowitz HM. Gold nanoparticles enhance the radiation therapy of a  murine squamous cell carcinoma. Phys Med Biol. 2010;55(11):3045-59.
  17. Liu CJ, Wang CH, Chen ST, Chen HH, Leng WH, Chien CC, et al. Enhancement of cell radiation sensitivity by pegylated gold nanoparticles. Phys Med Biol. 2010;55(4):931-45.
  18. Hirn S, Semmler-Behnke M, Schleh C, Wenk A, Lipka J, Schäffler M, et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. European journal of pharmaceutics and biopharmaceutics. 2011 Apr 1;77(3):407-16.
  19. Polf JC, Bronk LF, Driessen WHP, Arap W, Pasqualini R, Gillin M. Enhanced relative biological effectiveness of proton radiotherapy in tumor cells with internalized gold nanoparticles. Appl Phys Lett.  2011:193702-3.
  20. Geng F, Song K, Xing JZ, Yuan CZ, Yan S, Yang QF, et al. Thioglucose bound gold nanoparticles enhance radio-cytotoxic targeting of ovarian cancer. Nanotechnology. 2011;22(28).
  21. Yasui H, Takeuchi R, Nagane M, Meike S, Nakamura Y, Yamamori T, et al. Radiosensitization of tumor cells through endoplasmic reticulum stress induced by PEGylated nanogel containing gold nanoparticles. Cancer Lett. 2014;347(1):151-8.
  22. Khoshgard K, Hashemi B, Arbabi A, Rasaee MJ, Soleimani M. Radiosensitization effect of folate-conjugated gold nanoparticles on HeLa cancer cells under orthovoltage superficial radiotherapy techniques. Phys Med Biol. 2014;59(9):2249-63.
  23. Geng F, Xing JZ, Chen J, Yang R, Hao Y, Song K, et al. Pegylated glucose gold nanoparticles for improved in-vivo bio-distribution and enhanced radiotherapy on cervical cancer. J Biomed Nanotechnol. 2014;10(7):1205-16.
  24. Khosravi H, Mahdavi Gorabi A, Rahmani F, Ebadi A. Te Impact of Nano-Sized Gold Particles on the Target Dose EnhancementBased on Photon Beams Using by Monte Carlo Method. Nanomed Res J. 2016; 1(2):84-89
  25. Khosravi H, Hashemi B, Mahdavi SR, Hejazi P. Effect of gold nanoparticles on prostate dose distribution under Ir-192 internal and 18 MV external radiotherapy procedures using gel dosimetry and monte carlo method. J Biomed Phys Eng. 2015 Mar 4;5(1): 3-14.
  26. Prescribing, recording, and reporting photon beam therapy. Report #50. Bethesda, MD: International Commission on Radiation Units and Measurements; 1993.
  27. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. The lancet oncology. 2007 Jun 1;8(6):475-87.
  28. Van Herk M, Remeijer P, Rasch C, Lebesque J V. The probability of correct target dose: dose population histograms for deriving treatment margings in radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47: 1121-1135.
  29. Stroom JC, De Boer HC, Huizenga H, Visser AG. Inclusion of geometrical uncertainties in radiotherapy treatment planning by means of coverage probability. International Journal of Radiation Oncology* Biology* Physics. 1999 Mar 1;43(4):905-19.
  30. Crehange G, Mirjolet C, Gauthier M, Martin E, Truc G, Peignaux-Casasnovas K,et al. Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2012, 103:244–
  31. Skarsgard D, Cadman P, El-Gayed A, Pearcey R, Tai P, Pervez N, et al. Planning target volume margins for prostate radiotherapy using daily electronic portal imaging and implanted fiducial markers. Radiat Oncol. 2010, 5:52
  32. Borut Kragelj, MD, PhD, Department of Radiation Oncology, Institute of Oncology, Zaloška 2, SI-1000 Ljubljana, Slovenia; Setup error and its effect on safety margin in conformal radiotherapy of the prostate
  33. Zelefsky MJ, Valicenti RK, Goodman K, Perez CA. Prostate cancer. Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich RK, editors. Principles and practice of radiation oncology. 4th edition. Philadephia: Lippincot, Williams and Wilkins; 2004. p. 1692-762
  34. Zelefsky MJ, Crean D, Mageras GS, Lyass O, Happersett L, Ling CC, et al. Quantification and predictors of prostate position variability in 50 patients with multiple CT scans during conformal radiotherapy. Radiother Oncol 1999; 50: 225-34.
  35. Van Herk M, Remeijer P, Rasch C, Lebesque JV. The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. International Journal of Radiation Oncology* Biology* Physics. 2000 Jul 1;47(4):1121-35.
  36. Zhang X, Shan GP, Liu JP, Wang BB. Margin evaluation of translational and rotational set-up errors in intensity modulated radiotherapy for cervical cancer. Springerplus. 2016 Feb 24;5:153
  37. Adamson J, Wu Q, Yan D. Dosimetric effect of intrafraction motion and residual setup error for hypofractionated prostate intensity-modulated radiotherapy with online cone beam computed tomography image guidance. International Journal of Radiation Oncology* Biology* Physics. 2011 Jun 1;80(2):453-61.
  38. Polat B, Guenther I, Wilbert J, Goebel J, Sweeney RA, Flentje M, et al. Intra-fractional uncertainties in image-guided intensity-modulated radiotherapy (IMRT) of prostate cancer. Strahlentherapie und Onkologie. Organ der Deutschen Rontgengesellschaft [et al] 2008, 184:668–
  39. Laursen LV, Elstrom UV, Vestergaard A, Muren LP, Petersen JB, Lindegaard JC, et al. Residual rotational set up errors after daily cone beam CT image guided radiotherapy of locally advanced cervical cancer. 2012.

 

 

 

 

 

 

Iranian Journal of Medical Physics
Volume 20, Issue 5
September and October 2023
Pages 266-272

Files

History

  • Receive Date: 21 November 2021
  • Revise Date: 11 July 2022
  • Accept Date: 17 July 2022

Share

How to cite

Statistics